Plus Therapeutics’ (PSTV) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report published on Friday morning,Benzinga reports. The firm currently has a $9.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright lowered their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a report on Friday.

Plus Therapeutics Stock Performance

Shares of PSTV stock opened at $1.16 on Friday. The stock has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.24. The stock has a market cap of $6.84 million, a PE ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a 1 year low of $0.24 and a 1 year high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million. As a group, equities research analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.